Apremilast: PDE4 Inhibition in Psoriasis

Overview / Definition Apremilast is a small-molecule drug that selectively inhibits phosphodiesterase 4 (PDE4), an enzyme that degrades cyclic adenosine monophosphate (cAMP). By increasing cAMP levels, apremilast modulates the inflammatory pathways involved in psoriasis and other inflammatory conditions. It is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis. Epidemiology Psoriasis affects approximately 2-3% of the population worldwide, with varying prevalence across different ethnic groups. It commonly presents in adults, although it can also occur in children. The disease can significantly impact the quality of life and is associated with comorbidities such as obesity, metabolic syndrome, and cardiovascular disease. Pathophysiology / Mechanism Psoriasis is characterized by an overactive immune response leading to rapid skin cell proliferation and inflammation. The primary mechanism of action of apremilast involves: PDE4 Inhibition: Inhibition of PDE4 increases intracellular cAMP levels. Modulation of Cytokine Production: Increased cAMP levels lead to the inhibition of pro-inflammatory cytokines (e.g., TNF-α, IL-23) and the enhancement of anti-inflammatory cytokines (e.g., IL-10). Reduction of Keratinocyte Proliferation: By modulating the immune response, apremilast helps normalize the hyperproliferative state of keratinocytes in psoriasis. Clinical Presentation Patients with psoriasis typically present with: Plaque Psoriasis: Well-defined erythematous plaques covered with silvery scales. Psoriatic Arthritis: Joint pain and stiffness associated with skin lesions. Itching: Pruritus can be a significant symptom affecting daily life. Other variants of psoriasis include guttate, inverse, and pustular psoriasis, which may also respond to apremilast. Diagnosis / Workup The diagnosis of psoriasis is primarily clinical, based on characteristic skin findings. A skin biopsy may be performed in atypical cases to rule out other